Therapeutic Asset Ratings

105 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
RADIUM RA-223 Castration-resistant Prostate Cancer	Bayer	P4	BB (70)
RADIUM RA-223 Prostatic Neoplasms, Castration-Resistant	University of California, San Francisco	P4	BB (70)
RADIUM RA-223 Bone Metastases	University of California, San Francisco	P3	BB (69)
RADIUM RA-223 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	University of Washington	P3	BB (66)
RADIUM RA-223 Metastatic Castration-resistant Prostate Cancer	AstraZeneca	P4	BB (64)
Ferumoxytol Glioblastoma	Jonsson Comprehensive Cancer Center	P3	B (60)
RADIUM RA-223 Prostate Cancer	University of California, San Francisco	P3	B (60)
Cholestyramine Multiple Sclerosis	Sanofi	P3	B (59)
Ferumoxytol Multiple Sclerosis	Sanofi	P3	B (58)
lutetium (<sup>177</sup>Lu) zadavotide guraxetan Metastatic Castration-Resistant Prostate Cancer	Jonsson Comprehensive Cancer Center	P3	B (56)
HAFNIUM OXIDE Locally-Advanced Non-Small Cell Lung Cancer	M.D. Anderson Cancer Center	P1/2	CCC (54)
Cholestyramine Smoldering Plasma Cell Myeloma	City of Hope Medical Center	P2	CCC (53)
Colesevelam Early-stage Breast Cancer	Spanish Breast Cancer Research Group	P2	CCC (53)
Colesevelam HER2 Positive Breast Cancer	Spanish Breast Cancer Research Group	P2	CCC (53)
Colesevelam Hormone Receptor Positive	Spanish Breast Cancer Research Group	P2	CCC (53)
Ferumoxytol Epilepsy, Temporal Lobe	University of Alberta	P2	CCC (53)
IRON DEXTRAN Anemia, Iron Deficiency	Indiana University	P2	CCC (53)
lutetium (<sup>177</sup>Lu) zadavotide guraxetan Oligometastatic Prostate Carcinoma	Jonsson Comprehensive Cancer Center	P2	CCC (53)
lutetium (<sup>177</sup>Lu) zadavotide guraxetan Prostate Cancer	Jonsson Comprehensive Cancer Center	P2	CCC (53)
lutetium (<sup>177</sup>Lu) zadavotide guraxetan Stage IVB Prostate Cancer AJCC v8	Jonsson Comprehensive Cancer Center	P2	CCC (53)
POLY((N-(2-HYDROXYPROPYL)METHACRYLAMIDE)-CO-(METHACRYLOYL-GLY-PHE-LEU-GLY AMIDE WITH O-((TRANS-4-AMINOCYCLOHEXYL)CARBAMOYL)FUMAGILLOL)) (~0.91:0.09 X) Metastatic Triple-Negative Breast Cancer	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
RADIUM RA-223 Castrate Resistant Prostate Cancer	University of California, San Francisco	P2	CCC (53)
lutetium (<sup>177</sup>Lu) zadavotide guraxetan Prostate Adenocarcinoma	Jonsson Comprehensive Cancer Center	P2	CCC (51)
POLY((N-(2-HYDROXYPROPYL)METHACRYLAMIDE)-CO-(METHACRYLOYL-GLY-PHE-LEU-GLY AMIDE WITH O-((TRANS-4-AMINOCYCLOHEXYL)CARBAMOYL)FUMAGILLOL)) (~0.91:0.09 X) Breast Cancer	Memorial Sloan Kettering Cancer Center	P2	CCC (50)
IRON DEXTRAN Melanoma	Indiana University	P2	CCC (48)

Showing 1 to 25 of 105 assets

PreviousPage 1 of 5Next